Order Article Reprints

Jóri B, Vössing C, Pirngruber J, Willing EM, Arndt K, Falk M, Tiemann M, Heukamp LC, Hoffknecht P. The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations. Current Oncology. 2023; 30(10):8805-8814. https://doi.org/10.3390/curroncol30100635

Jóri, Balázs, Christine Vössing, Judith Pirngruber, Eva Maria Willing, Kathrin Arndt, Markus Falk, Markus Tiemann, Lukas C. Heukamp, and Petra Hoffknecht. 2023. "The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations" Current Oncology 30, no. 10: 8805-8814. https://doi.org/10.3390/curroncol30100635

Jóri, B., Vössing, C., Pirngruber, J., Willing, E. M., Arndt, K., Falk, M., Tiemann, M., Heukamp, L. C., & Hoffknecht, P. (2023). The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations. Current Oncology, 30(10), 8805-8814. https://doi.org/10.3390/curroncol30100635